A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).

被引：5

作者：

Zhu, Andrew X.

Finn, Richard S.

Ikeda, Masafumi

Sung, Max W.

Baron, Ari David

Kudo, Masatoshi

Okusaka, Takuji

Kobayashi, Masahiro

Kumada, Hiromitsu

Kaneko, Shuichi

Pracht, Marc

Mamontov, Konstantin

Meyer, Tim

Mody, Kalgi

Kubota, Tomoki

Dutcus, Corina E.

Saito, Kenichi

Siegel, Abby B.

Dubrovsky, Leonid

Llovet, Josep M.

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[2] Jiahui Int Canc Ctr, Boston, MA USA

[3] UCLA, David Geffen Sch Med, Med Ctr, Los Angeles, CA 90095 USA

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Tisch Canc Inst Mt Sinai, New York, NY USA

[6] Sutter Hlth, Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA

[7] Kindai Univ, Fac Med, Osaka, Japan

[8] Natl Canc Ctr, Tokyo, Japan

[9] Toranomon Gen Hosp, Tokyo, Japan

[10] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa, Japan

[11] Ctr Eugene Marquis, Rennes, France

[12] Altay Reg Oncol Hosp, Barnaul, Russia

[13] Royal Free London NHS Fdn Trust, London, England

[14] Eisai Inc, Woodcliff Lake, NJ USA

[15] Eisai & Co Ltd, Tokyo, Japan

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4519

引用

页数：2